PMC4489670_01
PET at diagnosis. Imaging demonstrates diffuse gastric wall thickening with SUVmax of 21.7 consistent with disease involvement.
cmo-9-2015-061f1.jpg
PMC4489670_01_cmo-9-2015-061f1.jpg
f1-cmo-9-2015-061
A positron emission tomography (PET) scan demonstrated diffuse hyper-metabolic gastric wall thickening measuring up to 3.9 cm along the upper curvature [standard uptake value (SUV) max./avg. 21.7/16.7] with minimally enlarged gastrohepatic lymph nodes (largest measuring 1.2 cm; SUV max./avg. 2.8/2.3) adjacent to the mass (Fig. 1).
End of treatment PET demonstrating resolution of previously seen FDG uptake and overall positive response to therapy.
cmo-9-2015-061f2.jpg
PMC4489670_01_cmo-9-2015-061f2.jpg
f2-cmo-9-2015-061
A PET scan at completion of chemotherapy demonstrated small residual FDG (fluorodeoxyglucose) activity in the body of the stomach measuring 1.9 cm x 0.7 cm (SUV 4.4) consistent with a positive response to therapy (Fig. 2).